Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while NEOS S&P 500 High Income ETF trades at $53.52 (market cap $12.59B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 12.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| MRVI | SPYI | |
|---|---|---|
Market Cap | $972.90M | $12.59B |
Volume | 4,325,710 | 1,834,804 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $54.42 |
52-Week Low | $2.83 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
